DIPROSONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DIPROSONE (DIPROSONE).
Corticosteroid with anti-inflammatory, immunosuppressive, and antiproliferative actions; binds to cytosolic glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators.
| Metabolism | Primarily hepatic via CYP3A4; also metabolized by other unknown enzymes. |
| Excretion | Primarily renal (approximately 75% as metabolites, 5-10% unchanged) and fecal (biliary, approximately 15%). |
| Half-life | Terminal elimination half-life: 28-54 hours. Clinical context: allows once-daily or alternate-day dosing for sustained anti-inflammatory effect. |
| Protein binding | Approximately 64-75% bound to corticosteroid-binding globulin and albumin. |
| Volume of Distribution | 0.5-1.1 L/kg; indicates extensive tissue distribution and sequestration in adipose tissue. |
| Bioavailability | Intramuscular: near 100%; Topical: low systemic absorption (approximately 1-5% through intact skin, higher with occluded or damaged skin). |
| Onset of Action | Intra-articular: 12-24 hours; Intramuscular: 24-48 hours; Topical: improvement within 1-2 weeks for psoriasis. |
| Duration of Action | Intra-articular: 1-2 weeks; Intramuscular: 1-3 weeks; Topical: effect persists for several days; clinical duration depends on dose and disease severity. |
| Action Class | Glucocorticoids |
| Brand Substitutes | Betamil Cream, Diproson 0.05% Cream, Betzee Cream, Azonate Cream, Cortiderm 0.05% Cream |
Diprosone (betamethasone dipropionate) is a topical corticosteroid. For adult dermatoses, apply a thin film to affected skin once daily (morning) and once nightly (evening). For moderate to severe conditions, apply twice daily. Rotate use to no more than 50 g per week (0.05% cream or ointment).
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment. Topical absorption is minimal; however, for extensive application or prolonged use, caution is advised in severe renal disease due to potential systemic effects (e.g., fluid retention). |
| Liver impairment | No specific dose adjustment for Child-Pugh classification. Use with caution in severe hepatic impairment due to potential decreased clearance of systemic corticosteroids. Avoid large surface area or prolonged use. |
| Pediatric use | For children (age <12 years): apply a thin film of 0.05% cream or ointment to affected area once or twice daily. Limit treatment duration to 2 weeks and avoid occlusive dressings. For infants, use the lowest effective dose due to increased systemic absorption. |
| Geriatric use | Elderly patients: use the lowest effective dose (apply once daily). Monitor skin atrophy and systemic effects, especially if applied to intertriginous areas. Avoid prolonged treatment (>2 weeks) without reassessment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DIPROSONE (DIPROSONE).
| Breastfeeding | Betamethasone (active component) is excreted into breast milk in low amounts; M/P ratio unknown. Topical use likely results in minimal exposure. However, high-dose systemic administration may suppress infant growth or interfere with endogenous corticosteroid production. Caution advised; use lowest effective dose. |
| Teratogenic Risk | First trimester: Corticosteroids are associated with a small increased risk of oral clefts (odds ratio ~3.4). Second/third trimester: Risk of intrauterine growth restriction (IUGR), preterm birth, and fetal adrenal suppression with prolonged systemic use. Topical use has low systemic absorption but high potency formulations may carry similar risks; avoid prolonged use. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to betamethasone dipropionate or any component of the formulation","Untreated bacterial, viral, or fungal skin infections","Perioral dermatitis","Rosacea"]
| Precautions | ["Systemic absorption with prolonged use may lead to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression","Local adverse reactions including skin atrophy, striae, telangiectasias, and secondary infection","Use with caution in patients with skin atrophy, renal impairment, or diabetes","Avoid use on face, groin, or axillae due to increased risk of atrophy","Do not use for ophthalmic purposes"] |
| Food/Dietary | No known food interactions. Avoid excessive intake of salty foods or diuretics as may increase risk of electrolyte imbalance if systemic absorption occurs. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose, blood pressure, and signs of infection. For prolonged systemic use: serial fetal growth ultrasound (every 4 weeks) to detect IUGR; amniotic fluid index; consider fetal adrenal suppression (neonatal hypoglycemia, poor feeding) if used near term. Topical: monitor for skin atrophy or striae. |
| Fertility Effects | No direct evidence of fertility impairment. However, high-dose or prolonged systemic corticosteroids may disrupt menstrual cycles and ovulatory function due to hypothalamic-pituitary-adrenal axis suppression. |
| Clinical Pearls | DIPROSONE (betamethasone dipropionate) is a high-potency topical corticosteroid. Use limited to short courses (≤2 weeks) for resistant dermatoses. Avoid on face, axillae, or groin due to risk of striae and atrophy. Systemic absorption can occur with prolonged use over large body surface areas, especially under occlusion. |
| Patient Advice | Apply a thin layer to affected area only, not to normal skin. · Wash hands after application unless treating hands. · Do not cover with bandages or dressings unless directed by physician. · Avoid use on face, underarms, or groin unless specifically instructed. · Use only as directed; do not use for longer than prescribed. · Inform physician if condition worsens or does not improve after 2 weeks. · Do not use for any condition other than that for which it was prescribed. |